Monograph Details
|
|
Central Nervous System
> Mood disorders
|
|
ZOLOFT |
| Manufacturer |
|
Pfizer Labs |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
SSRI. |
| Generic Name |
|
Sertraline (as HCl) 25mg, 50mg, 100mg; scored tabs. |
| Also |
|
• ZOLOFT ORAL CONCENTRATE
|
| Indications |
|
Depression. Premenstrual dysphoric disorder (PMDD). |
| Children |
|
Not recommended. |
| Adults |
|
Give once daily (AM or PM). Depression: initially 50mg/day, may increase at 1-week intervals; max 200mg/day. PMDD: give either for entire menstrual cycle or only during luteal phase. Luteal phase dosing: initially 50mg/day; if no response, may increase to 100mg/day, starting each cycle at 50mg/day for 3 days. Entire cycle dosing: initially 50mg/day, if no response, may increase by 50mg/cycle to max 150mg/day. |
| Contraindications |
|
During or within 14 days of MAOIs. Concomitant pimozide. Oral soln: concomitant disulfiram. |
| Precautions |
|
Monitor for mania/hypomania. Seizure disorders. Suicidal tendencies. Hepatic dysfunction (reduce dose or prolong dosing interval). Cardiac disease. Conditions that affect metabolism or hemodynamic response. Volume depleted. Reevaluate periodically in long-term use. Write Rx for smallest practical amount. Elderly. Labor & delivery. Pregnancy (Cat.C). Nursing mothers. |
| Interactions |
|
See Contraindications. Avoid alcohol. May potentiate or be potentiated by cimetidine, protein bound drugs (eg, warfarin, digitoxin). Caution with other CNS drugs and drugs metabolized by CYP2D6 (eg, tricyclics, flecainide, propafenone). Potentiates diazepam, tolbutamide. Monitor lithium, warfarin, tricyclics. Monitor patients on sumatriptan for serotonin syndrome (eg, weakness, incoordination, hyperreflexia). |
| Adverse Reactions |
|
GI upset, insomnia, somnolence, sexual dysfunction, tremor, dry mouth, sweating, anorexia, weight loss, anxiety, decreased libido, hyponatremia, weak uricosuric effect. |
| How Supplied |
Tabs 25mg—50
50mg, 100mg—100, 500
Conc—60mL (w. dropper) |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
